Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Bevacizumab and/or Pemetrexed in Advanced Non-Squamous NSCLC
NCT01107626Phase 3Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Oct 2010
- Primary completion
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab and pemetrexed in non-small cell lung cancer (NSCLC) (3 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Overall Survival at 5 years. Started Oct 2010; status: completed.
02
Drugs
bevacizumabpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01107626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01107626.